Evidence reviews – July 2022
The following documents contain the evidence that was used to develop the 2022 recommendations:
- Genetic testing for melanoma
- Use of sentinel lymph node biopsy in people with melanoma
- Surgical and histological excision margins for people with stage 0 to II melanoma
- Completion lymphadenectomy for micrometastatic nodal disease in stage III melanoma
- Use of sentinel lymph node biopsy for people with stage III melanoma with microsatellite lesions
- Systemic and localised anticancer treatment for people with stage IV and unresectable stage III melanoma
- Follow-up of people with melanoma
Evidence review supplements
- Health economic model report for evidence review A
- Health economic model report for evidence review F
- Network meta-analysis report for evidence review F
- Health economic model report for evidence review G
Evidence for the 2015 recommendations can be found in the 2015 full guideline on melanoma: assessment and management and supporting appendices:
This page was last updated: